Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FLIRT: 5-fluorouracil, leucovorin, irinotecan with temozolomide and bevacizumab in first-line MGMT-silenced MSS metastatic colorectal cancer
2024-515580-64-00Phase 2Authorised
- Sponsor
- Fondazione IRCCS - Istituto Nazionale dei Tumori di Milano
- Start
- Aug 2024
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, single-arm trial of fluorouracil, folinic acid, irinotecan, temozolomide and bevacizumab in metastatic colorectal adenocarcinoma (mCRC), sponsored by Fondazione IRCCS - Istituto Nazionale dei Tumori di Milano. Planned start Aug 2024; status: authorised.
02
Drugs
fluorouracilfolinic acidirinotecantemozolomidebevacizumab
03
Conditions
metastatic colorectal adenocarcinoma (mCRC)
Beyond the preview
Go deeper on 2024-515580-64-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515580-64-00.